<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Hotz, Christian</dc:creator>
  <dc:creator>Bourquin, Carole</dc:creator>
  <dc:date>2011</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Toll-like receptor (TLR) 7 agonists represent a promising strategy for the immunotherapy of cancer. We have recently investigated the influence of TLR tolerance on the efficacy of systemic tumor treatment with TLR7 ligands. We propose that considering the kinetics of receptor sensitivity highly improves the outcome of cancer immunotherapy.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/302510</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/302510/files/bou_sci.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4161/onci.1.2.18169</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>License undefined</dc:rights>
  <dc:source>Oncoimmunology. - 2012, vol. 1, no. 2, p. 227-228</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">TLR tolerance</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">TLR7</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">cancer immunotherapy</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">innate immunity</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/57</dc:subject>
  <dc:title xmlns:ns5="xml" ns5:lang="en">Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>